SOUTH SAN FRANCISCO, Calif., Feb. 08 2, 2022 (GLOBE NEWSWIRE) — Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthrough therapies against otherwise untreatable pathogen targets, today announced Piro Lito, MD, Ph.D. ., associate member and attending physician at Memorial Sloan Kettering Cancer Center (MSK), has joined its Scientific Advisory Board.
“We are thrilled to have Dr. Lito join our Scientific Advisory Board, comprised of industry leaders in oncology, drug development and discovery research,” said Chris Varma, Ph.D., Co-Founder, President and CEO. from Frontiers. “Dr. Lito is a world-renowned physician-scientist who studies KRAS mutations and their impact on intracellular signaling and cellular function. We look forward to working with him as we move our core program, a dual KRAS inhibitor inactive and activatedG12Ctowards the selection of clinical candidates.
Dr. Lito’s research focuses on proteins that stimulate cancer cell growth with the goal of uncovering the fundamental processes that govern tumor biology and identifying new therapies that prolong survival and improve quality of life for patients. with cancer. Specifically, his research has made several key contributions in the effort to better understand KRAS-induced cancers and to develop therapies that directly target mutant KRAS. Dr. Lito’s lab also examines the heterogeneity that exists within tumor cells and combines single-cell sequencing methods with biosensor technologies to map how different tumor populations respond to treatment, which could lead to a understanding of variable responses to cancer treatment. Dr. Lito obtained his Ph.D. in biochemistry and molecular biology and his medical degree from Michigan State University. He completed his residency in internal medicine at Beth Israel Deaconess Medical Center at Harvard Medical School and his fellowship in medical oncology at MSK. Dr. Lito is board certified in internal medicine and medical oncology.
Dr Lito added: “Frontier aims to develop drugs targeting some of the most important proteins for cancer cell growth and has the potential to impact cancer care. We know that KRAS periodically switches between enabled and inactive states. Blocking these two states could constitute an important innovation in the care of patients whose tumors harbor a KRAS mutation. I look forward to collaborating on these programs.
About Frontier Medicines
Frontier Medicines is a precision medicine company that has launched a powerful discovery and development platform designed to generate drugs against pathogenic proteins previously considered unmedicable. The company deploys its technologies in chemoproteomics, covalent drug discovery and machine learning to potentially develop breakthrough drugs for genetically defined patient populations, starting with cancer. Frontier is advancing its proprietary precision drug portfolio against key cancer drivers. The main program of the company is focused on KRASG12C and is distinctive in that it targets the direct inhibition of activated and inactive forms of KRASG12C. This KRAS mutation is most commonly found in patients with non-small cell lung, colorectal, and pancreatic cancers. For more information on how Frontier is boldly advancing science to defeat disease, visit www.frontiermeds.com and follow us on LinkedIn and Twitter.
Frontier Medicines Media: